Malaria

MAP Vaccine Tested for Safety and Immunogenicity in Phase I Trial

Published in Vaccine Weekly, April 5th, 2000

Immediate-type hypersensitivity reactions to a Plasmodium falciparum multi-antigen, CD peptide vaccine were exhibited in adult volunteers participating in a Phase I clinical trial, reported researchers from the United States.

"We tested the safety and immunogenicity of a synthetic Plasmodium falciparum multi-antigen, CS peptide (MAP) vaccine adsorbed to alum and mixed with the adjuvant QS-21," explained R. Edelman and colleagues from Aquila Biopharmaceuticals and from several universities in the United States.

Edelman et al. presented data from their study at the 48th Annual Meeting of the American Society of Tropical Medicine and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-04-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry